Practice Point®: Pulmonology

The treatment landscape for IPF and PPF is evolving rapidly, creating new opportunities for more personalized care. Explore the latest clinical evidence from the FIBRONEER program evaluating nerandomilast and the TETON trials evaluating inhaled treprostinil, alongside emerging therapies such as admilparant and deupirfenidone. Expert faculty examine novel mechanisms of action, treatment tolerability, combination therapy, and the pot...

Antifibrotic therapies can slow disease progression in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), but adverse effects and treatment discontinuation remain important challenges. Through a patient case and interactive clinical decision-making, explore practical approaches to managing gastrointestinal intolerance, adjusting doses, implementing temporary treatment interruptions, and supporting long-te...

When should persistent cough and dyspnea raise suspicion for interstitial lung disease (ILD) rather than more common respiratory conditions? Follow a 68-year-old patient whose nine-month diagnostic journey highlights missed clinical clues, delayed imaging, and opportunities for earlier intervention. Through interactive case-based questions, explore how clinical findings, pulmonary function testing, high-resolution computed tomograp...

Interstitial lung disease (ILD) encompasses a diverse group of disorders, making early recognition, accurate diagnosis, and timely referral challenging. In this expert-led module, explore the clinical, genetic, and environmental factors contributing to ILD heterogeneity, along with racial, ethnic, and socioeconomic disparities that influence patient outcomes. Through interactive audience polling and expert debate, examine the compe...

This module focuses on sustaining effective PAH management over time by integrating ongoing risk assessment with treatment persistence, tolerability, and evolving patient needs. It examines when continued therapy, escalation, transition, or carefully selected de-escalation may be appropriate, while emphasizing that failure to achieve or maintain low-risk status should prompt reassessment. The module also addresses adverse-effect mi...

This module explores how risk status, clinical trajectory, right ventricular function, hemodynamics, and patient-specific factors inform the selection and escalation of PAH therapy. It reviews therapies targeting the endothelin, nitric oxide, prostacyclin, and activin signaling pathways and considers how combination therapy and route of administration can be individualized according to disease severity and treatment goals. Particul...

This module examines structured risk assessment as the foundation for goal-directed management of pulmonary arterial hypertension (PAH), emphasizing that clinical stability is not synonymous with low-risk status. It reviews validated risk-stratification approaches and the integration of functional capacity, biomarkers, imaging, and hemodynamics to assess prognosis and treatment response. The module emphasizes routine reassessment a...

This module addresses the evolving management of patients who have achieved sustained clinical improvement but may experience treatment fatigue, adverse effects, or substantial treatment burden. It explores when therapy transition or de-escalation may be considered, emphasizing careful patient selection based on sustained clinical improvement, favorable risk status and hemodynamics, patient goals, and the ability to provide close f...

This module focuses on translating PAH treatment strategy into an individualized, sustainable regimen by considering route of administration, titration, tolerability, and treatment burden. It examines the practical differences among oral, inhaled, subcutaneous, and intravenous therapies and how disease severity, treatment response, adverse effects, patient preferences, and capacity for self-management influence therapeutic choices....

This module establishes risk assessment as the foundation of treatment decision-making in pulmonary arterial hypertension (PAH). It reviews multidimensional risk stratification, treatment goals, and the use of clinical, functional, biomarker, imaging, and hemodynamic findings to guide initial therapy and subsequent reassessment. Through a high-risk PAH case, the module illustrates how treatment intensity and sequencing should refle...

Idiopathic pulmonary fibrosis (IPF) presents ongoing challenges across the patient journey, from timely diagnosis to long-term disease management. Nonspecific symptoms often delays appropriate imaging and referral, while issues related to antifibrotic tolerability and treatment discontinuation may further complicate care. Clinicians must also consider changes in physiologic measures, including DLco, alongside emerging understanding...

Despite progress in disease identification and treatment strategies, PAH continues to carry considerable morbidity and mortality, highlighting the need for continued optimization of disease management.

Throughout this educational podcast, Dr. Vallerie McLaughlin highlights the latest advances in PAH presented at the International 2026 Conference in Orlando, FL.

Launch Date/Release Date: May 21 2026

Expiration Date: April 30, 2027

FACUL...

In this expert-led podcast, Dr. Nathan shares practical insights on recognizing early indicators of PH in the setting of ILD, interpreting key diagnostic findings, and applying effective risk stratification strategies. The discussion focuses on improving early detection and optimizing management to ultimately enhance outcomes for this high-risk patient population.

Launch Date/Release Date: May 7, 2026

Expiration Date: April 30, 2027

F...

New analyses show rising prevalence of progressive pulmonary fibrosis, persistent diagnostic delays, and continued gaps in antifibrotic use. Fresh data from major trials, including nerandomilast, inhaled treprostinil, admilparant, deupirfenidone, and nalbuphine ER for chronic cough, point to meaningful advances on the horizon. At the same time, patient-centered research highlights the need for clearer communication, coordinated car...

Chronic obstructive pulmonary disease (COPD) remains a major global health challenge, characterized by significant unmet needs in early diagnosis, personalized management, and coordinated multidisciplinary care. Many patients continue to receive suboptimal, non-guideline-aligned treatment, often leading to poorer outcomes, increased exacerbations, and diminished quality of life.

Join Dr. Bose and Dr. Han as they present key clinical...

Chronic obstructive pulmonary disease (COPD) remains a major global health challenge, characterized by significant unmet needs in early diagnosis, personalized management, and coordinated multidisciplinary care. Many patients continue to receive suboptimal, non-guideline-aligned treatment, often leading to poorer outcomes, increased exacerbations, and diminished quality of life.

Join Dr. Bose and Dr. Han as they present key clinical...

Chronic obstructive pulmonary disease (COPD) remains a major global health challenge, characterized by significant unmet needs in early diagnosis, personalized management, and coordinated multidisciplinary care. Many patients continue to receive suboptimal, non-guideline-aligned treatment, often leading to poorer outcomes, increased exacerbations, and diminished quality of life.

Join Dr. Bose and Dr. Han as they present key clinical...

Chronic obstructive pulmonary disease (COPD) remains a major global health challenge, characterized by significant unmet needs in early diagnosis, personalized management, and coordinated multidisciplinary care. Many patients continue to receive suboptimal, non-guideline-aligned treatment, often leading to poorer outcomes, increased exacerbations, and diminished quality of life.

Join Dr. Bose and Dr. Han as they present key clinical...